Phase I Trial of Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Advanced Soft Tissue Sarcoma
This study successfully determined the MTD of PLD in combination with IFO and rhG-CSF for advanced STS, offering a potentially valuable treatment option with a tolerable safety profile.
Authors
- Ling Peng (ORCID: https://orcid.org/0000-0003-3990-5248)
- Li Fan (ORCID: https://orcid.org/0009-0000-2721-0612)
- Rubo Cao (ORCID: https://orcid.org/0000-0001-5128-2181)
- Jing Chen (ORCID: https://orcid.org/0000-0001-8400-6861)
- Ting Ye (ORCID: https://orcid.org/0000-0003-4128-4209)
Institutions
- Union Hospital (HK)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-08-01
- DOI
- https://doi.org/10.2147/dddt.s529231
- Citations
- 1
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- American Society of Clinical Oncology